8-K 1 acer-8k_20210521.htm 8-K acer-8k_20210521.htm

 

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): May 21, 2021

 

ACER THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

001-33004

 

32-0426967

(State or other jurisdiction of
incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

 

One Gateway Center, Suite 351
300 Washington Street

Newton, Massachusetts

 

02458

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:  (844) 902-6100

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

  Name of Each Exchange on Which Registered

Common Stock, $0.0001 par value per share

ACER

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 


 

 

 

Item 5.07Submission of Matters to a Vote of Security Holders

 

The virtual Annual Meeting of Stockholders of Acer Therapeutics Inc. (the “Company”) was held on May 21, 2021 (the “Annual Meeting”).  Two proposals were submitted to stockholders as described in the Proxy Statement for the Annual Meeting and were approved by the Company’s stockholders at the Annual Meeting.  The proposals and the results of the stockholder votes are as follows.

 

 

1.

Proposal to elect five directors to serve until the 2022 annual meeting or until their successors are duly elected and qualified:

 

 

 

 

 

 

 

Broker

 

 

For

 

Withheld

 

Non-Votes

 

 

 

 

 

 

 

 

Stephen J. Aselage

6,137,663

 

35,197

 

2,816,304

 

Jason Amello

6,142,807

 

30,053

 

2,816,304

 

John M. Dunn

6,115,604

 

57,256

 

2,816,304

 

Michelle Griffin

6,137,537

 

35,323

 

2,816,304

 

Chris Schelling

6,142,919

 

29,941

 

2,816,304

 

 

2.

Proposal to ratify the appointment of BDO USA, LLP as independent auditors for the fiscal year ending December 31, 2021:

 

 

 

 

 

 

 

 

Broker

 

For

 

Against

 

Abstain

 

Non-Votes

 

 

 

 

 

 

 

 

 

8,951,533

 

8,953

 

28,678

 

0

 


2

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: May 24, 2021

ACER THERAPEUTICS INC.

 

 

 

 

 

 

By:

/s/ Harry S. Palmin 

 

 

 

Harry S. Palmin

 

 

 

Chief Operating Officer and Chief Financial Officer

 

 

 

3